Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[HIV-related symptoms].

A Potthoff1, N H Brockmeyer

  • 1Klinik für Dermatologie und Allergologie, Ruhr-Universität, Gudrunstrasse 56, 44791 Bochum, Deutschland. a.potthoff@klinikum-bochum.de

Der Urologe. Ausg. A
|November 23, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SGLT-2 inhibitors and GLP-1 receptor agonists in primary care pharmacotherapy of type 2 diabetes in people living with HIV versus HIV-negative controls: Findings from a multicenter study in Germany.

Primary care diabetes·2026
Same author

[Antibiotic treatment for sexually transmitted infections].

Dermatologie (Heidelberg, Germany)·2025
Same author

HIV pre-exposure prophylaxis during the SARS-CoV-2 pandemic: Results from a prospective observational study in Germany.

Frontiers in public health·2022
Same author

As monkeypox goes sexual: a public health perspective.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

Influence of dietary supplementation of short-chain fatty acid sodium propionate in people living with HIV (PLHIV).

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

Human papillomavirus type 67 in cutaneous squamous cell dysplasia and carcinoma.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
See all related articles

Highly active antiretroviral therapy (HAART) has transformed HIV infection, increasing survival and reducing opportunistic infections. However, challenges like drug resistance and long-term toxicity persist for patients.

Area of Science:

  • Infectious Diseases
  • Immunology
  • Virology

Context:

  • The advent of antiretroviral therapy has significantly altered the prognosis of Human Immunodeficiency Virus (HIV) infection.
  • Opportunistic infections and AIDS-defining malignancies are now less frequent.
  • Patient survival time has markedly increased.

Purpose:

  • To outline the current management of HIV infection based on German-Austrian therapy guidelines.
  • To highlight the importance of specialized centers for complex HIV care.
  • To identify factors contributing to therapeutic failure and ongoing challenges in HIV management.

Summary:

  • Current guidelines recommend initiating highly active antiretroviral therapy (HAART) upon symptom onset or CD4 cell count below 350/microl.

Related Experiment Videos

  • Monitoring involves regular CD4 cell counts and viral load assessments.
  • Therapeutic failure may result from drug interactions, viral resistance, or poor patient compliance.

    • Impact:

    • Despite treatment advances, HIV-infected individuals face significant psychological and social challenges.
    • Emerging issues include increasing viral multi-drug resistance and long-term toxicities such as lipodystrophy, osteoporosis, and cardiovascular disease.
    • Annually, 600-700 AIDS-related deaths still occur in Germany, underscoring the need for continued research and improved patient care.